

BC Cancer Protocol Summary for Alternative NEOAdjuvant Therapy for Triple Negative Breast Cancer using Dose Dense Therapy: CARBOplatin and PACLitaxel NAB (ABRAXANE) Followed by DOXOrubicin and Cyclophosphamide

Protocol Code: *BRLACPNACG*
Tumour Group: *Breast*
Contact Physician: *Dr. Angela Chan*

ELIGIBILITY:

Patients must have:

- Previous severe hypersensitivity reaction or anaphylaxis to PACLitaxel that is not manageable despite use of premedications, or
- Previous moderate PACLitaxel hypersensitivity reaction that cannot be managed by premedications due to a strong contraindication to high dose steroids, such as poorly controlled diabetes, and
- Been treated with curative intent breast cancer protocol BRLACTWACG

Patients should have:

- Adequate hematological, renal, and hepatic function

Note: Filgrastim (G-CSF) is not covered as a benefit at BC Cancer

EXCLUSIONS:

Patients must not have:

- Severe cardiovascular disease with LVEF less than 45%
- Severe hepatic dysfunction contraindicating PACLitaxel NAB (ABRAXANE) or DOXOrubicin
- Known hypersensitivity to E. coli derived products

CAUTIONS:

- Greater than or equal to grade 2 sensory or motor neuropathy

TESTS:

- Baseline: CBC & diff, platelets, bilirubin, ALT, GGT, LDH, alkaline phosphatase, creatinine
- Before each treatment: CBC & diff, platelets, creatinine (creatinine before each CARBOplatin treatment only)
- If clinically indicated: bilirubin, ALT, GGT, alkaline phosphatase, urea, creatinine, MUGA scan or echocardiogram

PREMEDICATIONS:

- Antiemetic protocol for highly emetogenic chemotherapy (see [protocol SCNAUSEA](#))

BC Cancer Protocol Summary BRLACPNACG

1 of 6

Activated: 1 Jan 2023 Revised: 1 Mar 2024 (Premedications and precautions clarified)

Warning: The information contained in these documents are a statement of consensus of BC Cancer professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is at your own risk and is subject to BC Cancer's terms of use available at www.bccancer.bc.ca/terms-of-use.

TREATMENT:

Drug	Dose	BC Cancer Administration Guideline
PACLitaxel NAB (ABRAXANE)	260 mg/m ²	IV over 30 minutes*
CARBOplatin	AUC 6 or 5 or 4 x (GFR + 25)	IV in 100 to 250 mL NS over 30 minutes

* in empty sterile bags and tubing with **15** micron filter; no specific material required for bag or tubing

- PACLitaxel NAB and CARBOplatin to be given every 21 days to complete total number of cycles in original BRLACTWACG protocol, followed by
- Four consecutive cycles of DOXOrubicin and cyclophosphamide to start 21 days after final cycle of PACLitaxel NAB and CARBOplatin

Drug	Dose	BC Cancer Administration Guideline
DOXOrubicin	60 mg/m ²	IV push
cyclophosphamide	600 mg/m ²	IV in 100 to 250 mL NS over 20 minutes to 1 hour
filgrastim (G-CSF)	5 mcg/kg/day Days 3 to 10 (or adjust as needed)**	subcutaneous

** reduce filgrastim treatment duration if ANC greater than 10 or intolerable bone pain. Filgrastim should not be stopped before the time of the predicted nadir from chemotherapy.

- Repeat every 14 days for 4 cycles

Measured GFR (e.g. nuclear renogram) is preferred whenever feasible, *particularly* in circumstances of co-morbidity that could affect renal function (third-space fluid accumulations, hypoproteinemia, potentially inadequate fluid intake, etc.). The lab reported GFR (MDRD formula) may be used as an alternative to the Cockcroft-Gault estimate of GFR; the estimated GFR reported by the lab or calculated using the Cockcroft-Gault equation should be capped at 125 mL/min when it is used to calculate the initial CARBOplatin dose. When a nuclear renogram is available, this clearance would take precedence.

Cockcroft-Gault Formula

$$\text{GFR} = \frac{1.04 \times (140 - \text{age in years}) \times \text{wt (kg)}}{\text{serum creatinine (micromol/L)}}$$

Note: The same method of estimation should be used throughout the treatment course (i.e. if lab reported GFR was used initially, this should be used for dosing in all subsequent cycles and not the Cockcroft-Gault estimate).

DOSE MODIFICATIONS:

1. Hematological

For cycles of PACLitaxel NAB and CARBOplatin only:

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	PAClitaxel NAB Dose	CARBOplatin Dose
greater than or equal to 1.5	and	greater than or equal to 100	100% (260 mg/m ²)	100%
1.0 to less than 1.5	and	greater than or equal to 100	220 mg/m ²	75%
less than 1.0	or	less than 100	delay until ANC greater than or equal to 1.5 and platelets greater than or equal to 100 then consider giving 220 mg/m ²	delay* until ANC greater than or equal to 1.5 and platelets greater than or equal to 100 then give 75%

*If repeated delays or dose reductions, consider reducing CARBOplatin to AUC of 5 from 6, or 4 from 5

For cycles of DOXOrubicin and cyclophosphamide only:

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Dose (both drugs)
greater than or equal to 1.0	and	greater than or equal to 100	100%
less than 1.0	and	greater than or equal to 100	delay for 1 week (or longer if needed), then give 100% dose if ANC greater than 1 and platelets greater than or equal to 100. Give filgrastim days 3 to 13 for remaining cycles.
greater than or equal to 1.0	and	less than 100	delay for 1 week (or longer if needed), then give 75% if ANC greater than 1 and platelets greater than or equal to 100
less than or equal to 1.0	and	less than 100	delay for 1 week (or longer if needed), then give 75% if ANC greater than 1 and platelets greater than or equal to 100

2. Febrile Neutropenia: PACLitaxel NAB

	1 st Occurrence	2 nd Occurrence
Febrile Neutropenia	Delay until recovery (ANC greater than or equal to $1.5 \times 10^9/L$ and platelets greater than or equal to $100 \times 10^9/L$), then dose reduce to 220 mg/m²**	Delay until recovery (ANC greater than or equal to $1.5 \times 10^9/L$ and platelets greater than or equal to $100 \times 10^9/L$), then dose reduce to 180 mg/m²**

**Dose reductions should be maintained for subsequent cycles and not re-escalated

3. Hepatic Dysfunction:

PACLitaxel NAB

ALT or AST		Bilirubin	PACLitaxel NAB
less than or equal to 10 x ULN	and	greater than 1 to less than or equal to 1.5 x ULN	100%
less than or equal to 10 x ULN	and/or	greater than 1.5 to less than or equal to 5 x ULN	80%*
greater than 10 x ULN	or	greater than 5 x ULN	hold

*may re-escalate dose if hepatic function normalizes and reduced dose is tolerated for at least 2 cycles

DOXOrubicin:

ALT or AST		Bilirubin (micromol/L)	Dose
2 to 3 x ULN		-	75%
greater than 3 x ULN	or	20 to 51	50%
-		51 to 85	25%
-		greater than 85	Do not administer

4. Renal dysfunction: No modification is required for PACLitaxel NAB in mild to moderate renal impairment. PACLitaxel NAB has not been studied in patients with creatinine clearance less than 30 mL/min.

If significant increase (greater than 20% or rises above the upper limit of normal) in creatinine, recheck/recalculate GFR and recalculate CARBOplatin dose using new GFR.

Dose modification may be required for cyclophosphamide. Refer to BC Cancer Drug Manual.

5. Sensory Neuropathy- PACLitaxel NAB

Grade	Toxicity	Dose – 1 st Occurrence	Dose – 2 nd Occurrence
1	Asymptomatic; loss of deep tendon reflexes or paresthesia (including tingling) but not interfering with function	Maintain dose	Maintain dose
2	Sensory alteration or paresthesia (including tingling) but not interfering with function, but not interfering with ADL	Maintain dose	Maintain dose
3	Sensory alteration or paresthesia interfering with ADL	Reduce dose to 220 mg/m ^{2**} Consider holding treatment until resolved to grade 2	Reduce dose to 180 mg/m ^{2**} Consider holding treatment until resolved to grade 2
4	Disabling	Hold treatment until resolved to grade 2, then reduce dose to 220 mg/m ^{2**} or discontinue further treatment at the discretion of physician	Hold treatment until resolved to grade 2, then reduce dose to 180 mg/m ^{2**} or discontinue further treatment at the discretion of physician

**Dose reductions should be maintained for subsequent cycles and not re-escalated.

6. Arthralgia and/or myalgia: If arthralgia and/or myalgia from PACLitaxel NAB of grade 2 (moderate) or higher is not relieved by adequate doses of NSAIDs or acetaminophen with codeine (e.g., **TYLENOL #3®**), a limited number of studies report a possible therapeutic benefit using:

- predniSONE 10 mg po bid x 5 days starting 24 hours post-PACLitaxel NAB
- Gabapentin 300 mg po on day before chemotherapy, 300 mg bid on treatment day, then 300 mg tid x 7 to 10 days

If arthralgia and/or myalgia persist, reduce subsequent PACLitaxel NAB doses to 220 mg/m².

PRECAUTIONS:

1. An albumin form of PACLitaxel may substantially affect a drug's functional properties relative to those of drug in solution. **Do not** substitute with or for other PACLitaxel formulations.
2. **Extravasation:** DOXOrubicin and PACLitaxel NAB cause pain and tissue necrosis (rarely for PACLitaxel NAB) if extravasated. Refer to BC Cancer Extravasation Guidelines.
3. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.
4. **Hypersensitivity:** Reactions to CARBOplatin may occur. Refer to BC Cancer Hypersensitivity Guidelines.
5. **Cardiac toxicity** has been reported rarely while patients receive PACLitaxel NAB. Severe cardiovascular events (3%), including chest pain, cardiac arrest, supraventricular tachycardia, edema, thrombosis, pulmonary thromboembolism, pulmonary emboli, and hypertension.
6. **Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution in patients with cardiac dysfunction. Cardiac assessment recommended once cumulative dose reaches 300 mg/m² (see BC Cancer Drug Manual).
7. **Drug interactions:** PACLitaxel NAB is metabolized by CYP2C8 and CYP3A4; caution should be exercised when administering with drugs which are CYP2C8 or CYP3A4 inducers or inhibitors.
8. **Theoretical risk of viral disease transmission,** due to human albumin component, is extremely remote.

Call Dr. Angela Chan or tumour group delegate at 604-877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.

References

1. Sánchez-Muñoz A, Jiménez B, García-Tapiador A, et al. Cross-sensitivity between taxanes in patients with breast cancer. *Clin Transl Oncol*. 2011 Dec;13(12):904-6.
2. Gianni L, Mansutti M, Anton A, et al. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. *JAMA Oncol*. 2018 Mar 1;4(3):302-308.
3. Untch M, Jackisch C, Schneeweiss A, et al. German Breast Group (GBG); Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators. Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. *Lancet Oncol*. 2016 Mar;17(3):345-356.
4. Yuan Y, Lee JS, Yost SE, et al. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. *Oncologist*. 2021 Mar;26(3):e382-e393.
5. Brufsky A. *nab*-Paclitaxel for the treatment of breast cancer: an update across treatment settings. *Exp Hematol Oncol*. 2017 Mar 22;6:7.